Skip to main content

Table 1 Baseline Characteristics of Patients Who Initiated Antiviral Therapy

From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

Characteristics

All Genotypes

Genotype 1

Genotype 2

Genotype 3

Genotype 4

Genotype 6

All patients

1021

506

16

314

13

166

Age, year

57.3 ± 11.2

57.1 ± 11.2

55.8 ± 11.5

56.5 ± 10.8

55.7 ± 13.6

59.2 ± 11.4

Male, n (%)

461 (45.2%)

236 (46.6%)

8 (50.0%)

133 (42.4%)

4 (30.8%)

77 (46.4%)

Race/Ethnicity, n (%)

 Thai

774 (75.8%)

402 (79.5%)

0

282 (90%)

3 (23%)

84 (50.6%)

 Asian

162 (15.9%)

71 (14%)

6 (37.5%)

24 (7.5%)

0

58 (34.9%)

 Others

85 (8.3%)

33 (6.5%)

10 (62.5%)

8 (2.5%)

10 (77%)

24 (14.5%)

Treatment experienced, n (%)

472 (46.2%)

263 (52%)

2 (12.5%)

148 (47.1%)

7 (53.8%)

50 (30.1%)

HBV co-infection, n (%)

27 (2.6%)

12 (2.4%)

1 (6.3%)

14 (4.5%)

0

0

HIV co-infection, n (%)

21 (2.1%)

13 (2.6%)

0

8 (2.5%)

0

0

Liver transplant recipient, n (%)

31 (3.0%)

16 (3.2%)

1 (6.3%)

9 (2.9%)

1 (7.7%)

4 (2.4%)

Hepatocellular carcinoma, n (%)

28 (2.7%)

10 (2%)

1 (6.3%)

13 (4.1%)

1 (7.7%)

3 (1.8%)

Cirrhosis, n (%)

521 (51.0%)

244 (48.2%)

4 (25%)

203 (64.6%)

7 (53.8%)

63 (38%)

Child-Turcotte-Pugh class, n (%)

 A

436 (83.7%)

219 (90%)

2 (50%)

157 (77%)

4 (57%)

54 (86%)

 B

78 (15%)

25 (10%)

2 (50%)

42 (21%)

3 (43%)

6 (9%)

 C

7 (1.3%)

0

0

4 (2%)

0

3 (5%)

MELD score

8.1 ± 2.6

7.8 ± 2.2

7.2 ± 1.1

8.7 ± 3.0

8.5 ± 2.5

8.0 ± 3.2

Platelet count < 100 × 109/μL, n (%)

193 (18.9%)

79 (15.6%)

0

84 (26.8%)

2 (15%)

28 (16.9%)

Albumin < 3.5 g/dL, n (%)

182 (17.8%)

69 (13.6%)

4 (25%)

76 (24.2%)

5 (38.5%)

27 (16.3%)

Total bilirubin > 1.1 mg/dL, n (%)

189 (18.5%)

87 (17.2%)

1 (16.7%)

77 (24.5%)

3 (23.1%)

21 (12.7%)

HCV RNA, mean ×106 IU/mL

3.6 ± 5.9

3.5 ± 6.2

4.2 ± 6.0

3.0 ± 4.2

2.4 ± 3.1

5.2 ± 7.3

≥2 × 106 IU/mL, n (%)

452 (44.3%)

228 (45.1%)

7 (43.8%)

118 (37.6%)

4 (30.8%)

93 (56.0%)

Creatinine clearance, mL/min/1.73 m2

  ≥ 90

424 (41.5%)

210 (41.5%)

9 (56.3%)

126 (40.1%)

7 (53.8%)

69 (41.6%)

 60–89

352 (34.5%)

178 (35.2%)

4 (25.0%)

111 (35.4%)

2 (15.4%)

56 (33.7%)

 30–59

81 (7.9%)

40 (7.9%)

1 (6.2%)

25 (8.0%)

3 (23.1%)

12 (7.2%)

  < 30

6 (0.6%)

3 (0.6%)

0

1 (0.3%)

0

2 (1.2%)

 Not reported

158 (15.5%)

75 (14.8%)

2 (12.5)

51 (16.2%)

1 (7.7%)

27 (16.3%)